BUZZ-Grail rises as $110 mln Samsung-backed funding boosts cancer test expansion

Grail

Grail

GRAL

0.00

** Shares of Grail GRAL.O rise 6.2% to $68.58 premarket

** The cancer test maker says it raised $110 mln via equity sale to Samsung affiliates to support growth and global expansion

** Adds that investment was priced at $70.05 per share

** Notes partnership with Samsung C&T aims to bring Galleri cancer screening test to South Korea and potentially to Japan and Singapore

** Galleri screens for over 50 cancers, including some without routine tests, company said

** Testing initially to be done in North Carolina lab - GRAL

** Test not approved by U.S. FDA and does not detect all cancers, GRAIL adds

** As of last close, stock down ~25% YTD


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.